Theresa Hickman

Vanderbilt University — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

5h-index941citations13works2.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(10), Cancer Research and Treatments(9), Viral Infectious Diseases and Gene Expression in Insects(4), Immunotherapy and Immune Responses(2), RNA Interference and Gene Delivery(2)

Publications13 total

Systemic inhibition of <i>de novo</i> purine biosynthesis prevents weight gain and improves metabolic health by increasing thermogenesis and decreasing food intake
2024· 2 citedOpen Access
P-187 Targeting glutamine metabolism and EGFR in RAS wildtype colorectal cancer
Annals of Oncology·2023· 1 citedOpen Access
2219 Intratumoral injection of the oncolytic immunotherapeutic Pexa-Vec (JX-594) in liver tumors and hepatocellular carcinoma: Recommendations for clinical practice
European Journal of Cancer·2015· 1 cited
Phase II trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC).
Journal of Clinical Oncology·2013· 14 cited
Phase IIb randomized trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), a targeted oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced hepatocellular carcinoma who have failed sorafenib treatment (TRAVERSE).
Journal of Clinical Oncology·2013· 9 cited
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Nature Medicine·2013· 754 citedOpen Access
A phase II trial of JX-594, a targeted multimechanistic oncolytic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC).
Journal of Clinical Oncology·2012· 3 cited
Phase IIb randomized trial of JX-594, a targeted multimechanistic oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced hepatocellular carcinoma who have failed sorafenib treatment (TRAVERSE).
Journal of Clinical Oncology·2012· 4 cited
Abstract LB-283: JX-594, a targeted multi-mechanistic oncolytic poxvirus, selectively infects tumor vasculature and causes acute tumor vascular disruption and necrosis in advanced cancer patients
Cancer Research·2011
Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy
Molecular Therapy·2011· 143 citedOpen Access
402 JX-594, a targeted multi-mechanistic oncolytic poxvirus, infects tumor vasculature and causes acute tumor vascular disruption and necrosis in advanced cancer patients
European Journal of Cancer Supplements·2010
124 RANDOMIZED PHASE II CLINICAL TRIAL OF INTRATUMORAL INJECTION OF JX-594, A TARGETED MULTI-MECHANISTIC ONCOLYTIC POXVIRUS, IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
Journal of Hepatology·2010· 3 citedOpen Access
Erythrocyte membrane microviscosity and phospholipid composition in lead workers.
Occupational and Environmental Medicine·1987· 7 citedOpen Access

Frequent Co-authors

Caroline J. Breitbach(10), David H. Kirn(10), Richard H. Patt(8), Jeong Heo(5), James M. Burke(5), Lara Longpre(5), Chang Won Kim(4), Riccardo Lencioni(4), John C. Bell(4), Tae-Ho Hwang(4), Mong Cho(3), Manijeh Daneshmand(3), Hyun Young Woo(3), M. Homerin(3), Monika Lusky(3), Leyo Ruo(2), Anne Moon(2), Kara Dubois(2), Kelley A. Parato(2), Ung Bae Jeon(2)